Core Viewpoint - Equillium, Inc. is advancing its investigational drug EQ504, targeting severe autoimmune and inflammatory disorders, with a Phase 1 study planned for mid-2026 and financial stability expected to support operations into 2029 [1][2]. Financial Performance - Revenue for Q4 2025 was $0, a decrease from $4.4 million in Q4 2024. For the full year 2025, no revenue was recognized compared to $41.1 million in 2024 [4]. - Research and development (R&D) expenses for Q4 2025 were $1.5 million, down from $7.3 million in Q4 2024. Total R&D expenses for 2025 were $12.8 million, significantly lower than $37.4 million in 2024 [5][6]. - General and administrative (G&A) expenses for Q4 2025 were $2.4 million, compared to $1.8 million in Q4 2024. For the full year, G&A expenses were $10.8 million, down from $11.9 million in 2024 [7]. - The net loss for Q4 2025 was $3.8 million, or $(0.04) per share, compared to a net loss of $5.8 million, or $(0.16) per share in Q4 2024. The full year net loss was $22.4 million, or $(0.39) per share, compared to $8.1 million, or $(0.23) per share in 2024 [8]. Cash Position - As of December 31, 2025, cash, cash equivalents, and short-term investments totaled $30.3 million, an increase from $22.6 million as of December 31, 2024. The company believes this, along with a recent $35 million financing, will fund operations into 2029 [9]. Clinical Development - EQ504 is a potent and selective AhR modulator designed for targeted local delivery in gastrointestinal diseases, including ulcerative colitis, and has potential applications in inflammatory lung diseases. The Phase 1 proof-of-mechanism study is set to begin in mid-2026, with data expected approximately six months later [1][10]. - The company is also evaluating EQ302, an oral bi-specific inhibitor for gastrointestinal indications, including celiac disease [5]. Strategic Focus - The CEO emphasized that 2025 was a transformative year, with a sharpened focus on EQ504 and strengthened financial resources to support its clinical development [2]. The company aims to position EQ504 as a best-in-class oral therapy for ulcerative colitis and other inflammatory diseases [2].

EQ504 for Ulcerative Colitis - EQ504, an AhR modulator, is being developed for ulcerative colitis with topline Phase 1 data expected in the second half of 2026 [8] - In vivo experiments show that colonic delivery of EQ504 results in a greater than 25-fold increase in exposure in colon tissues compared to blood [57, 58] - Clinical remission rates with AhR modulation are approximately 50%, compared to 20%-30% with current therapeutics [69] - The ulcerative colitis market is expected to exceed $12 billion in annual worldwide sales by 2030 [74] Itolizumab for acute graft-versus-host disease (aGVHD) - The Phase 3 EQUATOR study of Itolizumab in aGVHD did not show improvement in Day 29 outcomes but achieved statistically significant benefit in longer-term outcomes [7] - In the EQUATOR study, 44.9% of patients in the Itolizumab group achieved complete response (CR) at Day 99, compared to 28.6% in the placebo group (p-value 0.0354) [133] - Itolizumab Complete Responders had a statistically significant Duration of Complete Response with a median of 336 days vs 72 days observed on placebo (p-value 0.0166) [135, 136] - Itolizumab demonstrated statistically significant Failure Free Survival with a median of 154 days vs 70 days observed on Placebo (p-value 0.0430) [139, 140] EQ302 for Gastrointestinal Indications - EQ302, an oral IL-15/21 inhibitor, is in the preclinical stage targeting gastrointestinal indications [7] - There are over 750,000 non-responsive celiac disease patients in the United States, representing a multi-billion dollar annual market opportunity [188] Financial Status - As of March 31, 2025, Equillium had $14.5 million in total cash and investments [92]